PDCD1 and myasthenia gravis: Thus, administered anti-PD-1/PD-L1 monoclonal Abs may bind to the various non-tumor-specific immune subsets and induce the unwanted activation of the immune system, which may disturb the balance established between tolerance and autoimmunity and lead to irAEs such as MG (Figure 5).